Jazz Pharmaceuticals PLC- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 Jazz Pharmaceuticals PLC 公司

Jazz Pharmaceuticals PLC 是一家生物技术公司。该公司致力于为患有严重疾病的人开发药物。该公司的主要营销产品包括 Xywav（钙、镁、钾和钠羟基丁酸盐）口服溶液、Xyrem（钠羟基丁酸盐）口服溶液、Epidiolex（大麻二酚）口服溶液、Rylaze（重组欧文氏菌天冬酰胺酶-rywn）、Zepzelca（lurbinectedin）、Defitelio（去纤维苷酸钠）和 Vyxeos（柔红霉素和阿糖胞苷）注射用脂质体。Xywav（钙、镁、钾和钠羟基丁酸盐）口服溶液产品用于治疗 7 岁及以上发作性睡病患者的猝倒症或白天过度嗜睡 (EDS)。 Xyrem（羟基丁酸钠）口服溶液产品用于治疗 7 岁及以上发作性睡病患者的猝倒症或 EDS。Defitelio（去纤维苷酸钠）产品用于治疗肝静脉闭塞症 (VOD)。

公司简介

公司代码JAZZ

公司名称Jazz Pharmaceuticals PLC

上市日期Jan 18, 2012

CEOMs. Renee D. Gala

员工数量2800

证券类型Ordinary Share

年结日Jan 18

公司地址Fifth Floor, Waterloo Exchange

城市DUBLIN

上市交易所NASDAQ Global Select Consolidated

国家Ireland

邮编- -

电话35316347800

网址https://www.jazzpharma.com/

公司代码JAZZ

上市日期Jan 18, 2012

CEOMs. Renee D. Gala

公司高管

名称

名称/职务

职务

持股

持股变动

Mr. Seamus C. Mulligan

Independent Director

1.27M

+8.67%

Mr. Bruce C. Cozadd

Chairman of the Board

335.96K

-0.30%

Dr. Robert Iannone, M.D.

Executive Vice President, Global Head - Research and Development, Chief Medical Officer

31.28K

--

Ms. Renee D. Gala

President, Chief Executive Officer, Director

29.39K

--

Mr. Kenneth W. (Ken) O'Keefe

Independent Director

27.68K

--

Ms. Neena M. Patil, J.D.

Executive Vice President, Chief Legal Officer

21.63K

-15.90%

Mr. Philip L. Johnson

Chief Financial Officer, Executive Vice President

15.00K

--

Dr. Norbert G. Riedel, Ph.D.

Independent Director

12.22K

--

Ms. Anne O'Riordan

Independent Director

11.07K

--

Mr. Rick E. Winningham

Lead Independent Director

8.96K

--

名称

名称/职务

职务

持股

持股变动

Mr. Seamus C. Mulligan

Independent Director

1.27M

+8.67%

Mr. Bruce C. Cozadd

Chairman of the Board

335.96K

-0.30%

Dr. Robert Iannone, M.D.

Executive Vice President, Global Head - Research and Development, Chief Medical Officer

31.28K

--

Ms. Renee D. Gala

President, Chief Executive Officer, Director

29.39K

--

Mr. Kenneth W. (Ken) O'Keefe

Independent Director

27.68K

--

Ms. Neena M. Patil, J.D.

Executive Vice President, Chief Legal Officer

21.63K

-15.90%

收入明细

单位: USD更新时间: 7月6日周日

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

业务USD

名称

营收

占比

Xywav

344.80M

38.40%

Epidiolex/epidyolex

217.74M

24.25%

Rylaze

94.23M

10.50%

Zepzelca

63.03M

7.02%

High-sodium oxybate AG royalty revenue

48.95M

5.45%

Other

129.09M

14.38%

地区USD

名称

营收

占比

United States

797.95M

88.87%

Europe

83.61M

9.31%

All Others

16.29M

1.81%

业务

地区

业务USD

名称

营收

占比

Xywav

344.80M

38.40%

Epidiolex/epidyolex

217.74M

24.25%

Rylaze

94.23M

10.50%

Zepzelca

63.03M

7.02%

High-sodium oxybate AG royalty revenue

48.95M

5.45%

Other

129.09M

14.38%

股东统计

更新时间: 7月22日周二

持股股东

股东类型

持股股东

占比

The Vanguard Group, Inc.

9.91%

BlackRock Institutional Trust Company, N.A.

8.61%

LSV Asset Management

4.08%

Dimensional Fund Advisors, L.P.

3.85%

State Street Global Advisors (US)

3.25%

Other

70.31%

持股股东

占比

The Vanguard Group, Inc.

9.91%

BlackRock Institutional Trust Company, N.A.

8.61%

LSV Asset Management

4.08%

Dimensional Fund Advisors, L.P.

3.85%

State Street Global Advisors (US)

3.25%

Other

70.31%

股东类型

持股股东

占比

Investment Advisor

53.78%

Investment Advisor/Hedge Fund

31.14%

Hedge Fund

9.59%

Research Firm

3.30%

Individual Investor

3.06%

Pension Fund

2.14%

Bank and Trust

1.04%

Venture Capital

0.85%

Sovereign Wealth Fund

0.18%

机构持股

更新时间: 7月1日周二

报告期

机构数

持股数

持股占比

持股变动

2025Q2

1196

63.65M

105.18%

-6.19M

2025Q1

1235

63.66M

105.15%

-6.35M

2024Q4

1202

62.66M

103.17%

-6.51M

2024Q3

1172

61.48M

99.60%

-6.16M

2024Q2

1167

61.28M

97.21%

-6.97M

2024Q1

1163

63.08M

101.15%

-2.43M

2023Q4

1156

61.76M

98.11%

-3.48M

2023Q3

1158

61.08M

96.76%

-4.05M

2023Q2

1197

61.00M

95.34%

-4.11M

2023Q1

1207

61.36M

96.91%

-3.79M

股东持股明细

名称

持股数

占比

持股变动

变动比例

公告日期

The Vanguard Group, Inc.

5.99M

9.91%

-18.47K

-0.31%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

5.21M

8.61%

-33.38K

-0.64%

Mar 31, 2025

LSV Asset Management

2.47M

4.08%

-64.88K

-2.56%

Mar 31, 2025

Dimensional Fund Advisors, L.P.

2.33M

3.85%

+293.36K

+14.42%

Mar 31, 2025

State Street Global Advisors (US)

1.97M

3.25%

-2.23K

-0.11%

Mar 31, 2025

Capital World Investors

1.93M

3.19%

+4.45K

+0.23%

Mar 31, 2025

EcoR1 Capital, LLC

1.71M

2.82%

--

Mar 31, 2025

JP Morgan Asset Management

1.50M

2.48%

+71.69K

+5.01%

Mar 31, 2025

Columbia Threadneedle Investments (US)

1.35M

2.24%

-136.12K

-9.14%

Mar 31, 2025

Fuller & Thaler Asset Management Inc.

1.33M

2.2%

+391.66K

+41.69%

Mar 31, 2025

持股ETF

更新时间: 8月2日周六

机构名称

占比

AdvisorShares Pure Cannabis ETF

5.57%

Cambria Cannabis ETF

4.57%

SPDR S&P Pharmaceuticals ETF

3.68%

iShares U.S. Pharmaceuticals ETF

3.29%

First Trust NASDAQ Pharmaceuticals ETF

2.98%

Invesco Pharmaceuticals ETF

2.62%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

2.61%

First Trust Health Care Alphadex Fund

1.87%

Tema Neuroscience and Mental Health ETF

1.86%

VictoryShares Small Cap Free Cash Flow ETF

1.71%

AdvisorShares Pure Cannabis ETF

占比5.57%

Cambria Cannabis ETF

占比4.57%

SPDR S&P Pharmaceuticals ETF

占比3.68%

iShares U.S. Pharmaceuticals ETF

占比3.29%

First Trust NASDAQ Pharmaceuticals ETF

占比2.98%

Invesco Pharmaceuticals ETF

占比2.62%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

占比2.61%

First Trust Health Care Alphadex Fund

占比1.87%

Tema Neuroscience and Mental Health ETF

占比1.86%

VictoryShares Small Cap Free Cash Flow ETF

占比1.71%

分红派息

近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股

公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

Jazz Pharmaceuticals PLC

115.040USD

Jazz Pharmaceuticals PLC

115.040

概览

公司

财务